Details
Stereochemistry | ACHIRAL |
Molecular Formula | C30H29ClN6O3 |
Molecular Weight | 557.043 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3
InChI
InChIKey=JWNPDZNEKVCWMY-VQHVLOKHSA-N
InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
Molecular Formula | C30H29ClN6O3 |
Molecular Weight | 557.043 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: http://adisinsight.springer.com/drugs/800021154Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26089701 | https://www.ncbi.nlm.nih.gov/pubmed/15715478
Sources: http://adisinsight.springer.com/drugs/800021154
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26089701 | https://www.ncbi.nlm.nih.gov/pubmed/15715478
Neratinib (HKI-272) is a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. Neratinib is a modified form of the discontinued compound pelitinib, and was originally being develoAdditionally, phase II development of oral neratinib as a neoadjuvant therapy for breast cancer, as a second-line therapy for non-small cell lung cancer, and for other solid tumours is also in progress in numerous countries worldwide. ped by Wyeth (later Pfizer). Oral neratinib is awaiting approval as an extended adjuvant therapy for breast cancer in the EU and in the US. Blocking HER2 function by a small molecule kinase inhibitor, such as neratinib, represents an attractive alternate strategy for the growth inhibition of HER2-positive tumours.
Originator
Sources: http://adisinsight.springer.com/drugs/800021154
Curator's Comment: # Wyeth (now Pfizer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15715478 |
59.0 nM [IC50] | ||
Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15715478 |
92.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NERLYNX Approved UseNERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy. Launch Date2017 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73.1 ng/mL |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NERATINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
81.5 ng/mL |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NERATINIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
76.3 ng/mL |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
NERATINIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
71.8 ng/mL |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
NERATINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1060 ng × h/mL |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NERATINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
1110 ng × h/mL |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NERATINIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
1640 ng × h/mL |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
NERATINIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
891 ng × h/mL |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
NERATINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.6 h |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NERATINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
22.7 h |
240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NERATINIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
14.3 h |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
NERATINIB blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
12.6 h |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
NERATINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
NERATINIB plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 49.5 years (range: 42-63 years) n = 6 Health Status: unhealthy Condition: Non–small cell lung cancer | breast cancer Age Group: 49.5 years (range: 42-63 years) Sex: M+F Population Size: 6 Sources: |
DLT: Diarrhea... Disc. AE: Fatigue... Dose limiting toxicities: Diarrhea (grade 3, 3 patients) AEs leading todiscontinuation/dose reduction: Fatigue (all grades, 5 patients) Sources: |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
DLT: Diarrhea, Diarrhea... Dose limiting toxicities: Diarrhea (all grades, 95%) Sources: Diarrhea (grade 3, 40%) Diarrhea (grade 4, 0.1%) |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Disc. AE: Nausea, Abdominal pain... Other AEs: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea (grade 3, 2%) Other AEs:Abdominal pain (grade 3, 2%) Abdominal pain upper (grade 3, 2%) Abdominal pain lower (grade 3, 2%) Vomiting (grade 3, 3%) Fatigue (grade 3, 2%) Alanine aminotransferase increased (grade 3, 1%) Alanine aminotransferase increased (grade 4, 0.2%) Nausea (all grades, 43%) Sources: Abdominal pain (all grades, 36%) Abdominal pain upper (all grades, 36%) Abdominal pain lower (all grades, 36%) Vomiting (all grades, 26%) Stomatitis (all grades, 14%) Aphthous stomatitis (all grades, 14%) Mouth ulceration (all grades, 14%) Oral mucosal blistering (all grades, 14%) Mucosal inflammation (all grades, 14%) Oropharyngeal pain (all grades, 14%) Oral pain (all grades, 14%) Glossodynia (all grades, 14%) Glossitis (all grades, 14%) Cheilitis (all grades, 14%) Stomatitis (grade 3, 0.3%) Aphthous stomatitis (grade 3, 0.3%) Mouth ulceration (grade 3, 0.3%) Oral mucosal blistering (grade 3, 0.3%) Mucosal inflammation (grade 3, 0.3%) Oropharyngeal pain (grade 3, 0.3%) Oral pain (grade 3, 0.3%) Glossodynia (grade 3, 0.3%) Glossitis (grade 3, 0.3%) Cheilitis (grade 3, 0.3%) Dyspepsia (all grades, 10%) Dyspepsia (grade 3, 0.4%) Abdominal distension (all grades, 5%) Abdominal distension (grade 3, 0.3%) Dry mouth (all grades, 3%) Dry mouth (grade 3, 0.1%) Fatigue (all grades, 27%) Alanine aminotransferase increased (all grades, 9%) Aspartate aminotransferase increased (all grades, 7%) Aspartate aminotransferase increased (grade 3, 0.5%) Aspartate aminotransferase increased (grade 4, 0.2%) Urinary tract infection (all grades, 5%) Urinary tract infection (grade 3, 0.1%) Weight decreased (all grades, 5%) Weight decreased (grade 3, 0.1%) Decreased appetite (all grades, 12%) Decreased appetite (grade 3, 0.2%) Dehydration (all grades, 4%) Dehydration (grade 3, 0.9%) Dehydration (grade 4, 0.1%) Muscle spasms (all grades, 11%) Muscle spasms (grade 3, 0.1%) Epistaxis (all grades, 5%) Rash (all grades, 18%) Rash erythematous (all grades, 18%) Rash follicular (all grades, 18%) Generalized rash (all grades, 18%) Rash pruritic (all grades, 18%) Rash pustular (all grades, 18%) Maculopapular rash (all grades, 18%) Rash papular (all grades, 18%) Dermatitis (all grades, 18%) Dermatitis acneiform (all grades, 18%) Toxic skin eruption (all grades, 18%) Rash (grade 3, 0.6%) Rash erythematous (grade 3, 0.6%) Rash follicular (grade 3, 0.6%) Generalized rash (grade 3, 0.6%) Rash pruritic (grade 3, 0.6%) Rash pustular (grade 3, 0.6%) Maculopapular rash (grade 3, 0.6%) Rash papular (grade 3, 0.6%) Dermatitis (grade 3, 0.6%) Dermatitis acneiform (grade 3, 0.6%) Toxic skin eruption (grade 3, 0.6%) Dry skin (all grades, 6%) Nail disorder (all grades, 8%) Paronychia (all grades, 8%) Onychoclasis (all grades, 8%) Nail discoloration (all grades, 8%) Nail toxicity (all grades, 8%) Nail growth abnormal (all grades, 8%) Nail dystrophy (all grades, 8%) Nail disorder (grade 3, 0.3%) Paronychia (grade 3, 0.3%) Onychoclasis (grade 3, 0.3%) Nail discoloration (grade 3, 0.3%) Nail toxicity (grade 3, 0.3%) Nail growth abnormal (grade 3, 0.3%) Nail dystrophy (grade 3, 0.3%) Skin fissures (all grades, 2%) Skin fissures (grade 3, 0.1%) |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Other AEs: Bilirubin increased, Bilirubin increased... Other AEs: Bilirubin increased (all grades, 11.1%) Sources: Page: p. 117Bilirubin increased (grade 3, 0.1%) Alkaline phosphatase (all grades, 22.7%) Creatinine increased (all grades, 12.5%) Creatinine increased (grade 4, 0.1%) Creatinine increased (grade 3, 0.1%) Hypercalcemia (all grades, 11.2%) Hypercalcemia (grade 4, 0.2%) Hypercalcemia (grade 3, 0.4%) Hypermagnesemia (all grades, 5.2%) Hypermagnesemia (grade 4, 0.1%) Hypermagnesemia (grade 3, 0.9%) Hypernatremia (all grades, 10.3%) Hypernatremia (grade 4, 0.1%) Hypernatremia (grade 3, 0.1%) Hypoalbuminemia (all grades, 8.4%) Hypoalbuminemia (grade 3, 0.1%) Hypocalcemia (all grades, 48.9%) Hypocalcemia (grade 4, 0.9%) Hypocalcemia (grade 3, 0.1%) Hypokalemia (all grades, 7.5%) Hypokalemia (grade 4, 0.1%) Hypokalemia (grade 3, 0.3%) Hypomagnesemia (all grades, 7.2%) Hypomagnesemia (grade 4, 0.2%) Hypomagnesemia (grade 3, 0.4%) Hyponatremia (all grades, 11.6%) Hyponatremia (grade 3, 0.9%) |
180 mg 1 times / day steady, oral Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, 56.5 years (range: 46-90 years) n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 56.5 years (range: 46-90 years) Sex: F Population Size: 6 Sources: |
DLT: Diarrhea... Disc. AE: Fatigue... Dose limiting toxicities: Diarrhea (grade 3, 1 patient) AEs leading todiscontinuation/dose reduction: Fatigue (all grades, 1 patient) Sources: |
320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Disc. AE: Diarrhea, Fatigue... Other AEs: Abdominal pain, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (all grades, 92%) Other AEs:Fatigue (all grades, 49%) Abdominal pain (all grades, 21%) Sources: Nausea (all grades, 54%) Vomiting (all grades, 49%) Anorexia (all grades, 33%) Rash (all grades, 8%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Fatigue | all grades, 5 patients Disc. AE |
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 49.5 years (range: 42-63 years) n = 6 Health Status: unhealthy Condition: Non–small cell lung cancer | breast cancer Age Group: 49.5 years (range: 42-63 years) Sex: M+F Population Size: 6 Sources: |
Diarrhea | grade 3, 3 patients DLT, Disc. AE |
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 49.5 years (range: 42-63 years) n = 6 Health Status: unhealthy Condition: Non–small cell lung cancer | breast cancer Age Group: 49.5 years (range: 42-63 years) Sex: M+F Population Size: 6 Sources: |
Diarrhea | all grades, 95% DLT, Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Diarrhea | grade 3, 40% DLT, Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Diarrhea | grade 4, 0.1% DLT, Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dyspepsia | all grades, 10% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Muscle spasms | all grades, 11% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Decreased appetite | all grades, 12% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Aphthous stomatitis | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Cheilitis | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Glossitis | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Glossodynia | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Mouth ulceration | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Mucosal inflammation | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Oral mucosal blistering | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Oral pain | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Oropharyngeal pain | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Stomatitis | all grades, 14% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dermatitis acneiform | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dermatitis | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Generalized rash | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Maculopapular rash | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash erythematous | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash follicular | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash papular | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash pruritic | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash pustular | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Toxic skin eruption | all grades, 18% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Skin fissures | all grades, 2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Vomiting | all grades, 26% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Fatigue | all grades, 27% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dry mouth | all grades, 3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal pain lower | all grades, 36% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal pain upper | all grades, 36% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal pain | all grades, 36% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dehydration | all grades, 4% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nausea | all grades, 43% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal distension | all grades, 5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Epistaxis | all grades, 5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Urinary tract infection | all grades, 5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Weight decreased | all grades, 5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dry skin | all grades, 6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Aspartate aminotransferase increased | all grades, 7% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail discoloration | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail disorder | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail dystrophy | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail growth abnormal | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail toxicity | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Onychoclasis | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Paronychia | all grades, 8% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Alanine aminotransferase increased | all grades, 9% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dry mouth | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Muscle spasms | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Skin fissures | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Urinary tract infection | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Weight decreased | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Decreased appetite | grade 3, 0.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal distension | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Aphthous stomatitis | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Cheilitis | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Glossitis | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Glossodynia | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Mouth ulceration | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Mucosal inflammation | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail discoloration | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail disorder | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail dystrophy | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail growth abnormal | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nail toxicity | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Onychoclasis | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Oral mucosal blistering | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Oral pain | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Oropharyngeal pain | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Paronychia | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Stomatitis | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dyspepsia | grade 3, 0.4% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Aspartate aminotransferase increased | grade 3, 0.5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dermatitis acneiform | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dermatitis | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Generalized rash | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Maculopapular rash | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash erythematous | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash follicular | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash papular | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash pruritic | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash pustular | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Rash | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Toxic skin eruption | grade 3, 0.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dehydration | grade 3, 0.9% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Alanine aminotransferase increased | grade 3, 1% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal pain lower | grade 3, 2% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal pain upper | grade 3, 2% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Abdominal pain | grade 3, 2% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Fatigue | grade 3, 2% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Nausea | grade 3, 2% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Vomiting | grade 3, 3% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Dehydration | grade 4, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Aspartate aminotransferase increased | grade 4, 0.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Alanine aminotransferase increased | grade 4, 0.2% Disc. AE |
240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: |
Hypernatremia | all grades, 10.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Bilirubin increased | all grades, 11.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypercalcemia | all grades, 11.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hyponatremia | all grades, 11.6% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Creatinine increased | all grades, 12.5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Alkaline phosphatase | all grades, 22.7% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypocalcemia | all grades, 48.9% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypermagnesemia | all grades, 5.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypomagnesemia | all grades, 7.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypokalemia | all grades, 7.5% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypoalbuminemia | all grades, 8.4% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Bilirubin increased | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Creatinine increased | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypernatremia | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypoalbuminemia | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypocalcemia | grade 3, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypokalemia | grade 3, 0.3% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypercalcemia | grade 3, 0.4% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypomagnesemia | grade 3, 0.4% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypermagnesemia | grade 3, 0.9% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hyponatremia | grade 3, 0.9% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Creatinine increased | grade 4, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypermagnesemia | grade 4, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypernatremia | grade 4, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypokalemia | grade 4, 0.1% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypercalcemia | grade 4, 0.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypomagnesemia | grade 4, 0.2% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Hypocalcemia | grade 4, 0.9% | 240 mg 1 times / day steady, oral Recommended Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: Page: p. 117 |
unhealthy, 52 years n = 1408 Health Status: unhealthy Condition: HER2-positive early-stage breast cancer Age Group: 52 years Sex: F Population Size: 1408 Sources: Page: p. 117 |
Fatigue | all grades, 1 patient Disc. AE |
180 mg 1 times / day steady, oral Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, 56.5 years (range: 46-90 years) n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 56.5 years (range: 46-90 years) Sex: F Population Size: 6 Sources: |
Diarrhea | grade 3, 1 patient DLT, Disc. AE |
180 mg 1 times / day steady, oral Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: |
unhealthy, 56.5 years (range: 46-90 years) n = 6 Health Status: unhealthy Condition: Breast cancer Age Group: 56.5 years (range: 46-90 years) Sex: F Population Size: 6 Sources: |
Abdominal pain | all grades, 21% | 320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Anorexia | all grades, 33% | 320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Vomiting | all grades, 49% | 320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Fatigue | all grades, 49% Disc. AE |
320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Nausea | all grades, 54% | 320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Rash | all grades, 8% | 320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Diarrhea | all grades, 92% Disc. AE |
320 mg 1 times / day steady, oral MTD Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy, 57 years (range: 34-80 years) n = 39 Health Status: unhealthy Condition: cancers Age Group: 57 years (range: 34-80 years) Sex: M+F Population Size: 39 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes [IC50 1 uM] | yes (co-administration study) Comment: NERATINIB increases digoxin Cmax& AUC Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208051Orig1s000MultidisciplineR.pdf#page=67 Page: - |
|||
yes [Inhibition 10 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: ketoconazole increased Cmax and AUC by 3.2- and 4.8-fold respectively, rifampin (a strong CYP3A4 inducer) decreased the Cmax and AUC of neratinib by 76% and 87%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208051Orig1s000MultidisciplineR.pdf#page=65 Page: - |
|||
minor | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. | 2004 Jun 1 |
|
Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. | 2011 |
|
Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. | 2011 Mar 10 |
|
Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
Patents
Sample Use Guides
Patients who received 40, 80, or 120 mg experienced no dose-limiting toxicities. The study determined the maximum tolerated dose at 320 mg, with 240 mg being the therapeutic dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26260909
both very low (10 nM) and physiologically attainable concentrations of neratinib (133 nM) significantly inhibited the autophosphorylation of HER2/neu and activation of S6 in primary carcinosarcoma cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:26 GMT 2023
by
admin
on
Fri Dec 15 16:25:26 GMT 2023
|
Record UNII |
JJH94R3PWB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
699119
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
||
|
WHO-ATC |
L01XE45
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
||
|
NDF-RT |
N0000175605
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NERATINIB
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL180022
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
9915743
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
5252
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
61397
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
SUB32232
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
DTXSID70220132
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
DB11828
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
8878
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
JJH94R3PWB
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
1940643
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
698387-09-6
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
C49094
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
m7827
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
JJH94R3PWB
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
SS-120
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
876310-02-0
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
100000124443
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY | |||
|
Neratanib
Created by
admin on Fri Dec 15 16:25:26 GMT 2023 , Edited by admin on Fri Dec 15 16:25:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
OFF-TARGET->INHIBITOR |
INHIBITOR
Percent inhibition of specific binding
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
CELL->INHIBITOR |
CELL PROLIFERATION
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
BINDER->LIGAND |
ex vivo protein binding of neratinib in human plasma samples from clinical study in healthy subjects as determined using ult racentrifugation was 88%
BINDING
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
CUMULATIVE EXCRETION |
URINE
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
Neratinib concentration at 10 microM
Percent inhibition of specific binding
|
||
|
TARGET -> INHIBITOR |
± 4.37
IRREVERSIBLE INHIBITOR
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
Cyclin D1 expression in BT474 cells
INHIBITOR
IC50
|
||
|
CELL->INHIBITOR |
CELL PROLIFERATION
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
HER2 ligand-independent receptor phosphorylation in BT474
IRREVERSIBLE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
IRREVERSIBLE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
TARGET -> INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
EGFR-dependent receptor phosphorylation in A431 cells
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
METABOLIC ENZYME -> NON-INDUCER |
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
OFF-TARGET->INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
|
||
|
OFF-TARGET->INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
TARGET -> INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
CUMULATIVE EXCRETION |
FECAL
|
||
|
BINDER->LIGAND |
In vitro, neratinib was highly bound (N 99 %) to human plasma proteins at clinical exposures. click to edit
BINDING
|
||
|
TARGET -> INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
TRANSPORTER -> INHIBITOR |
Neratinib concentration at 10 microM
INHIBITOR
Percent inhibition of specific binding
|
||
|
TARGET -> INHIBITOR |
Radioligand binding assay
BINDING
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
Inhibition of HER2 kinase activity (in autophosphorylation assay; Neratinib IC50 = 39 nM)
INHIBITOR
IC50
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
IC50 for HER2 kinase activity was up to 19 fold higher when compared to neratinib.
INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
Dose PHARMACOKINETIC PHARMACOKINETIC |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
Route of Administration PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
Dose PHARMACOKINETIC PHARMACOKINETIC |
|
||
Cmax | PHARMACOKINETIC |
|
Dose PHARMACOKINETIC PHARMACOKINETIC |
|
||